Navigation Links
InterMune to Present at Deutsche Bank Biotech Boston Confab
Date:11/7/2008

BRISBANE, Calif., Nov. 7 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Daniel G. Welch, Chairman, Chief Executive Officer and President of InterMune, will present at Deutsche Bank's 2008 Biotech Boston Confab on November 11, 2008 at 4:00 p.m. EST.

To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at http://www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a research and development portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
2. InterMune to Release Third Quarter 2008 Financial Results on November 6
3. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
4. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
5. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
6. InterMune to Present at Canaccord Adams Conference
7. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
8. InterMune to Present at BMO Healthcare Conference
9. InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
10. InterMune to Present at Jefferies Healthcare Conference
11. InterMune to Present at Goldman Sachs Healthcare and Needham & Co. Biotechnology and Medical Technology Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... ... July 26, 2017 , ... Vincent R. Burton, MBBS, FRCA, ... licensed by the Bahamas’ National Stem Cell Ethics Committee (NSCEC). , Dr. Burton ... the West Indies. He went on to complete residency training in the United Kingdom ...
(Date:7/26/2017)... ... July 25, 2017 , ... Avery Products ... that enable short-run digital printing, is proud to announce that it has won ... Wizard online software available at avery.com/GHS . The products were recently honored ...
(Date:7/26/2017)... , ... July 25, 2017 , ... ... and manufacturing services that are necessary in the preparation and development of human ... biorepository facility operates under the US Food and Drug Administration’s (FDA) Current Good ...
(Date:7/26/2017)... , ... July 26, 2017 , ... ... company for the improvement of crop productivity and economics for the food, feed ... The scope of the agreement includes the research and development of microbiome-based seed ...
Breaking Biology Technology:
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... Report on Form 10-K on Thursday April 13, 2017 with the ... The ... section of the Company,s website at http://www.nxt-id.com  under "SEC Filings," ... 2016 Year Highlights: Acquisition of ...
(Date:4/11/2017)... Research and Markets has announced the addition ... their offering. ... tracking market to grow at a CAGR of 30.37% during the ... 2017-2021, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
(Date:4/5/2017)... -- The Allen Institute for Cell Science today announces the ... and dynamic digital window into the human cell. The ... of deep learning to create predictive models of cell ... growing suite of powerful tools. The Allen Cell Explorer ... available resources created and shared by the Allen Institute ...
Breaking Biology News(10 mins):